AltheaDx Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 45

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $49.1M

AltheaDx General Information

Description

Operator of a commercial-stage molecular diagnostics company intended to specialize in the field of pharmacogenomics. The company's bioinformatics platform and PGx product testing portfolio assist healthcare providers in identifying optimal drugs for their patients as well as dosing guidelines based on a patient's genetic make-up, current prescription regimen and other key factors, enabling healthcare providers to make timely and evidence-based decisions.

Contact Information

Website
www.altheadx.com
Formerly Known As
Althea Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3030 Bunker Hill Street
  • Suite 300
  • San Diego, CA 92109
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Castle Biosciences
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3030 Bunker Hill Street
  • Suite 300
  • San Diego, CA 92109
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AltheaDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 26-Apr-2022 $49.1M Completed Generating Revenue
9. Later Stage VC 04-Dec-2020 Completed Generating Revenue
8. Later Stage VC 11-Oct-2019 Completed Generating Revenue
7. Later Stage VC 15-Jan-2019 Completed Generating Revenue
6. Later Stage VC 09-Aug-2018 Completed Generating Revenue
5. Later Stage VC (Series D) 25-Apr-2017 Completed Generating Revenue
4. Later Stage VC (Series C) 14-Dec-2015 Completed Generating Revenue
3. IPO 09-Mar-2015 Cancelled Generating Revenue
2. Early Stage VC (Series B) 19-Jun-2013 $7.25M $13.2M Completed Generating Revenue
1. Early Stage VC (Series A) 13-Apr-2010 $6M $6M Completed Generating Revenue
To view AltheaDx’s complete valuation and funding history, request access »

AltheaDx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D1
Series D2
Series C
Series B 3,954,952 $0.000100 $0.08 $1 $1 $2.44 0.73%
Series A 831,923 $0.000100 $0.14 $1.78 $1.78 $3.33 0.2%
To view AltheaDx’s complete cap table history, request access »

AltheaDx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a commercial-stage molecular diagnostics company intended to specialize in the field of pharmacogenomics. Th
Drug Discovery
San Diego, CA
45 As of 2022

Singapore, Singapore
 

Miami, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AltheaDx Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NalaGenetics Venture Capital-Backed Singapore, Singapore
Igenomix Formerly PE-Backed Miami, FL
Ambry Genetics Private Equity-Backed Aliso Viejo, CA
Fulgent Genetics Corporation El Monte, CA
OneOme Venture Capital-Backed Minneapolis, MN
To view AltheaDx’s complete competitors history, request access »

AltheaDx Patents

  • 37

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • Pending

  • Expiring in next 12 mo

AltheaDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090110639-A1 Predicting vaccine efficacy Inactive 07-Jun-2007
US-20080124726-A1 Apparatus which generates single cell aqueous reaction volumes in a flow channel for use detection pf preferential protein expression in cell; high throughput assay Inactive 26-May-2006
EP-2029781-A2 Biochemical analysis of partitioned cells Inactive 26-May-2006
EP-2029781-A4 Biochemical analysis of partitioned cells Inactive 26-May-2006
EP-2636755-A1 Biochemical analysis of partitioned cells Inactive 26-May-2006 G01N33/56966
To view AltheaDx’s complete patent history, request access »

AltheaDx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AltheaDx Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
ALMA Life Sciences Venture Capital Minority
Ally Bridge Group PE/Buyout Minority
Biobrit Venture Capital Minority
Greg Bisconti Angel (individual) Minority
Telegraph Hill Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

AltheaDx FAQs

  • When was AltheaDx founded?

    AltheaDx was founded in 2008.

  • Who is the founder of AltheaDx?

    François Ferré Ph.D is the founder of AltheaDx.

  • Where is AltheaDx headquartered?

    AltheaDx is headquartered in San Diego, CA.

  • What is the size of AltheaDx?

    AltheaDx has 45 total employees.

  • What industry is AltheaDx in?

    AltheaDx’s primary industry is Drug Discovery.

  • Is AltheaDx a private or public company?

    AltheaDx is a Private company.

  • What is the current valuation of AltheaDx?

    The current valuation of AltheaDx is .

  • What is AltheaDx’s current revenue?

    The current revenue for AltheaDx is .

  • How much funding has AltheaDx raised over time?

    AltheaDx has raised $79.8M.

  • Who are AltheaDx’s investors?

    ALMA Life Sciences, Ally Bridge Group, Biobrit, Greg Bisconti, and Telegraph Hill Partners are 5 of 7 investors who have invested in AltheaDx.

  • Who are AltheaDx’s competitors?

    NalaGenetics, Igenomix, Ambry Genetics, Fulgent Genetics, and OneOme are some of the 6 competitors of AltheaDx.

  • When was AltheaDx acquired?

    AltheaDx was acquired on 26-Apr-2022.

  • Who acquired AltheaDx?

    AltheaDx was acquired by Castle Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »